Every 8-K that ArriVent BioPharma, Inc. (AVBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVBP filings page.
ArriVent BioPharma, Inc. (AVBP) dosed the first patient in the U.S. in the Phase 1 trial of ARR-002, a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate for ovarian and endometrial cancer. The trial evaluates safety, tolerability, efficacy and pharmacokinetics in advanced or metastatic ovarian or endometrial cancer. ARR-002 is the company’s second ADC to enter the clinic. In August 2026, ArriVent entered an exclusive licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize ARR-002 in Greater China, defined as mainland China, Hong Kong, Macau and Taiwan; ArriVent retained all other rights. ARR-002 is also known as AV-P138-ADC and is described as a 2+2 format ADC with site-specific vcMMAE conjugation at a drug-to-antibody ratio of 4.
ArriVent BioPharma, Inc. (AVBP) said its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR). Median BICR PFS was 11.0 months with 240 mg, 8.4 months with 160 mg, and 9.5 months in the control arm; the 240 mg-versus-control comparison had a p-value of 0.0654.
Investigator-assessed median PFS was 11.1, 8.3 and 7.1 months for the 240 mg, 160 mg and control arms, respectively; confirmed objective response rates by BICR were 60%, 35% and 33%. Overall-survival data were not yet mature, although a trend toward improvement was observed. ArriVent reported no new safety signals and said FURVENT's safety profile was consistent with previous clinical studies.
ArriVent BioPharma, Inc. entered a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals, granting Allist an exclusive, sublicensable, royalty-bearing license to develop and commercialize ARR-002 in Greater China, while ArriVent retains rights elsewhere and a right to manufacture in the territory. ArriVent may receive up to $80.6 million in upfront and milestone payments, plus tiered royalties in the mid-single digit to low double-digit range on ARR-002 net sales in the licensed territory, with royalties payable for a defined patent, regulatory, or time-based royalty term.
For the quarter ended June 30, 2026, ArriVent reported a net loss of $49.9 million on operating expenses of $52.7 million, compared with a $31.4 million net loss a year earlier. For the first six months of 2026, net loss was $93.2 million, slightly improved from $95.8 million in the prior-year period as total operating expenses declined. The company ended June 30, 2026 with $154.7 million in cash and cash equivalents, $218.4 million in short-term investments, and total stockholders’ equity of $366.8 million, providing substantial capital to advance firmonertinib and its ADC pipeline, including ARR-217 and ARR-002.
ArriVent BioPharma, Inc. reported results of its 2026 annual meeting of stockholders held via live webcast. Stockholders elected three Class II directors—James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D.—to serve until the 2029 annual meeting.
Of 46,368,442 common shares eligible to vote as of April 21, 2026, 33,418,793 shares, or 72.07%, were present or represented by proxy, satisfying quorum requirements. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
ArriVent BioPharma, Inc. filed a prospectus supplement tied to its existing at-the-market equity offering program. Under this supplement, the company may offer and sell shares of its common stock with an aggregate offering price of up to $250,000,000 from time to time through Jefferies LLC as sales agent.
The at-the-market sales are made under an Open Market Sale Agreement dated February 3, 2025, and are covered by ArriVent’s automatic shelf registration statement on Form S-3ASR, which became effective upon filing. The company also filed the sales agreement and related legal opinions as exhibits.
ArriVent BioPharma reported first quarter 2026 results and highlighted progress across its oncology pipeline. The company is running two pivotal firmonertinib Phase 3 trials in uncommon EGFR-mutant non-small cell lung cancer, with topline monotherapy data in frontline EGFR exon 20 insertion NSCLC expected in mid-2026 and the global ALPACCA PACC-mutant study continuing enrollment.
ArriVent also advanced its antibody-drug conjugate programs: ARR-002 received FDA clearance of its IND, with initial clinical development planned in ovarian and endometrial cancers, and ARR-217 continues in a Phase 1 trial for gastrointestinal tumors. Management reiterated a projected cash runway into the fourth quarter of 2027.
Financially, for the quarter ended March 31, 2026, research and development expenses were $37.6 million versus $61.3 million a year earlier, while general and administrative expenses rose to $8.5 million from $5.5 million. Net loss narrowed to $43.3 million from $64.4 million, or $0.96 per share compared with $1.90 per share. Cash and cash equivalents were $62.1 million and short-term investments were $264.3 million as of March 31, 2026.
ArriVent BioPharma, Inc. reported that it will present two preclinical poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego from April 17-22. The information is furnished under Regulation FD and an accompanying press release is included as an exhibit.
One poster covers preclinical findings for EGFR inhibitor firmonertinib, including high-resolution crystal structure data that support an ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer. The other focuses on ARR-002, a novel dual-target MUC16/NaPi2b tetravalent antibody drug conjugate for ovarian and endometrial cancers, describing its preclinical characterization and planned advancement toward clinical evaluation, with additional data to be highlighted in an oral mini-symposium presentation.
ArriVent BioPharma, Inc. reported full year 2025 results and updated its oncology pipeline. The company is advancing firmonertinib through two global Phase 3 trials in first-line non-small cell lung cancer with uncommon EGFR mutations, with topline data from the exon 20 insertion study expected in mid-2026 and a projected cash runway into 3Q 2027.
For the year ended December 31, 2025, ArriVent recorded total operating expenses of 177,534 (in thousands), driven mainly by research and development expenses of 153,351 (in thousands), reflecting investment in firmonertinib and its ADC portfolio. The company reported a net loss of 166,308 (in thousands), compared with 80,488 (in thousands) in 2024, and total assets of 333,169 (in thousands), including cash, cash equivalents and investments.
Management highlighted continued progress for ARR-217, a CDH17-targeted antibody-drug conjugate in an ongoing Phase 1 trial for gastrointestinal tumors, and indicated plans to advance additional ADC candidates toward the clinic, broadening ArriVent’s focus beyond lung cancer into multiple solid tumors.
ArriVent BioPharma, Inc. filed a current report to note that it has released its financial results for the third quarter ended September 30, 2025. On November 10, 2025, the company issued a press release with these quarterly results, which is attached as Exhibit 99.1.
The company specifies that the press release and the related disclosure are being furnished rather than filed under U.S. securities laws, meaning they are not subject to certain liability provisions and are not automatically incorporated into other SEC filings.
ArriVent BioPharma, Inc. filed a report describing a new corporate update related to its lung cancer drug development work. The company issued a press release announcing that it presented the final analysis of firmonertinib monotherapy data from its global phase 1b study in EGFR PACC mutant non-small cell lung cancer at the 2025 World Conference on Lung Cancer.
The press release is included as Exhibit 99.1 and most of its contents are incorporated by reference into this report, while being furnished rather than filed for securities law purposes.
ArriVent BioPharma, Inc. disclosed that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company furnished that press release as Exhibit 99.1 to this Form 8-K, and also included a Cover Page Interactive Data File as Exhibit 104. The filing states the press release and related information are being furnished and are not to be deemed "filed" under the Securities Exchange Act.
The Form 8-K itself does not include the financial figures or operating metrics; the substantive results are contained in the press release referenced as Exhibit 99.1.
ArriVent BioPharma (Nasdaq: AVBP) furnished an 8-K to disclose positive interim results from its global Phase 1b FURTHER study evaluating first-line firmonertinib monotherapy in patients with EGFR P-loop and α-C-helix compressing (PACC) mutant non-small cell lung cancer (NSCLC).
At the 240 mg dose, investigators observed a median progression-free survival (mPFS) of 16.0 months and a median duration of response of 14.6 months (cut-off 3 Mar 2025). Tumor shrinkage of ≥30%—the study’s threshold for overall response—occurred in 68.2% of first-line patients at 240 mg versus 43.5% at 160 mg. Among patients presenting with brain metastases, 41% achieved a confirmed response and 53% recorded ≥30% tumor reduction, underscoring central-nervous-system activity.
Safety remained favorable: no Grade 4 or 5 treatment-related adverse events (TRAEs) and no treatment discontinuations; the most common TRAEs were diarrhea, elevated hepatic enzymes, rash, stomatitis and dry skin.
Based on these data, AVBP will launch ALPACCA (FURMO-006), a randomized global Phase 3 trial using the 240 mg dose, with first-patient-in targeted for the second half of 2025. The press release detailing the findings is furnished as Exhibit 99.1; information under Item 7.01 is not deemed “filed” for Exchange Act purposes.